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Abstract
Background: Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant
syndrome. The National Cancer Institute (NCI) has recommended the Revised Bethesda guidelines
for screening HNPCC. There has been a great deal of research on the value of these tests in other
countries. However, literature about the Chinese population is scarce. Our objective is to detect
and study microsatellite instability (MSI) and mismatch repair (MMR) gene germline mutation
carriers among a Chinese population with colorectal cancer.
Methods: In 146 prospectively recruited consecutive patients with clinically proven colorectal
cancer, MSI carriers were identified by analysis of tumor tissue using multiplex fluorescence
polymerase chain reaction (PCR) using the NCI recommended panel and classified into
microsatellite instability-low (MSI-L), microsatellite instability-high (MSI-H) and microsatellite stable
(MSS) groups. Immunohistochemical staining for MSH2, MSH6 and MLH1 on tissue microarrays
(TMAs) was performed, and methylation of the MLH1 promoter was analyzed by quantitative
methylation specific PCR (MSP). Germline mutation analysis of blood samples was performed for
MSH2, MSH6 and MLH1 genes.
Results: Thirty-four out of the 146 colorectal cancers (CRCs, 23.2%) were MSI, including 19 MSI-
H CRCs and 15 MSI-L CRCS. Negative staining for MSH2 was found in 8 CRCs, negative staining
for MSH6 was found in 6 CRCs. One MSI-H CRC was negative for both MSH6 and MSH2.
Seventeen CRCs stained negatively for MLH1. MLH1 promoter methylation was determined in 34
MSI CRCs. Hypermethylation of the MLH1 promoter occurred in 14 (73.7%) out of 19 MSI-H
CRCs and 5 (33.3%) out of 15 MSI-L CRCs. Among the 34 MSI carriers and one MSS CRC with
MLH1 negative staining, 8 had a MMR gene germline mutation, which accounted for 23.5% of all
MSI colorectal cancers and 5.5% of all the colorectal cancers. Five patients harbored MSH2
germline mutations, and three patients harbored MSH6 germline mutations. None of the patients
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had an MLH1 mutation. Mutations were commonly located in exon 7 and 12 of MSH2 and exon 5
of MSH6. Right colonic lesions and mucinous carcinoma were not common in MSI carriers.
Conclusion: Our data may imply that the characteristics of HNPCC in the Chinese population
are probably different from those of Western countries. Application of NCI recommended criteria
may not be effective enough to identify Chinese HNPCC families. Further studies are necessary to
echo or refute our results so as to make the NCI recommendation more universally applicable.
Background
HNPCC is an autosomal dominant syndrome, which
accounts for about 1–5% of colorectal cancer [1]. HNPCC
patients are characterized by earlier symptoms, more
mucinous carcinoma, more synchronous and meta-
chronous colorectal tumors and more extra-colonic
tumors, but have better survival [1,2]. It is believed that
HNPCC is secondary to a germline mutation resulting in
a defective MMR gene. A defective MMR gene results in
increased DNA replication errors and MSI, which causes
the occurrence of tumors in different organs, especially in
the colorectum. Identification of HPNCC families is
important because the diagnosis, treatment and follow up
of these individuals should be different from those with
sporadic colorectal cancer [2]. However, the clinical diag-
nosis of HNPCC patients is very difficult for lack of spe-
cific clinical phenotype. Though Amsterdam criteria I and
II were established for HNPCC diagnosis[3,4], many
HNPCC families still do not meet the criteria.
MSI is an important phenotype of MMR gene mutation. In
1997, the National Cancer Institute (NCI) recommended
screening MSI CRCs using the Bethesda guidelines [5].
After compiling evidence from years of global studies and
follow up, NCI revised the Bethesda guidelines in 2004,
which is called the revised Bethesda standard [6]. NCI rec-
ommended screening of HNPCC based on detection of
MSI in the tumor and loss of expression of a MMR gene
using immunohistochemistry (IHC) staining [6]. How-
ever, until now, there has been no research about the
applicability of the NCI recommendations to the Chinese
population with colorectal cancers. The aim of this study
is to detect and study MSI carrier and mismatch repair
(MMR) gene germline mutation carriers among a Chinese
population with colorectal cancer.
Methods
Patients
Data were prospectively collected from 158 consecutive
colorectal cancer patients who received surgical treat-
ments in the National Colorectal Center of the Third Affil-
iated Hospital of Nanjing University of Traditional
Chinese Medicine (NUTCM) from October 2004 to June
2006. All patients signed an informed consent before the
study. Patients who had histologically proven carcinoma
and received operative treatment in our hospital were
included in the study. Patients were excluded if they: (1)
had evidence of concomitant ulcerative colitis, (2) pre-
sented with clinically unresectable diseases, (3) were diag-
nosed with FAP and other polyposis syndromes, (4)
refused operative treatment or refused to participate in the
study. This study was approved by the ethical committee
of the NUTCM.
Extraction of genomic DNA
Fresh tissue samples of tumor and matched normal
mucosa were obtained from the surgical specimen once it
was removed. DNA was extracted using a tissue DNA
extraction kit from the Beijing Bio-lab Materials Institute
(Beijing, China) and was stored at -80°C until analysis.
Synthesis of fluorescent primer
A reference panel of 5 MSI markers recommended by NCI:
BAT-26, BAT-25, D2S123, D5S346 and D17S250 were
used in this study. The primers of BAT-40 and MYCL were
also applied. The fluorescent primers were synthesized at
Applied Biosystem Company (Foster City, CA) with a pre-
viously published method [6,7].
Microsatellite instability analysis
Microsatellite instability was analyzed according to a
method previously reported [6,7]. Briefly, the 5 microsat-
ellites were amplified by multiple PCR. The reaction sys-
tem consisted of 1 μL of template (extracted genomic
DNA, 100 ng), 4 μL of mixed primers (primer mix) and 15
μL of ABI Prism True Allele PCR Premix (containing
AmpliTaq Gold DNA Polymerase buffer, magnesium
chloride and dNTPs) (Applied Biosystems Company).
The reaction initially underwent pre-denature at 95°C for
15 minutes, then 30 cycles of: denaturation at 94°C for 1
minute, annealing at 56°C for 1 minute and extension at
72°C for 1 minute were performed. An additional exten-
sion at 72°C for 25 minutes was performed subsequently.
PCR reaction product (1 μL) was then mixed with 0.4 μL
LIZ (internal standard) and 9 μL of formamide. Heat
denaturation was performed on the mixture at 95°C for 5
minutes, and the sample was kept at 4°C for 5 minutes.
Then the product was put in a 96 well plate, and capillary
electrophoresis was performed with an AB13100-Avant
sequencer (Applied Biosystem Shanghai Division, Shang-
hai, China) for 45 minutes. Data was automatically ana-BMC Cancer 2008, 8:44 http://www.biomedcentral.com/1471-2407/8/44
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lyzed with Genotyper 2.5 software (Applied Biosystem
Shanghai Division) and the original data was generated.
The electrophoresis was then repeated on the next day to
ensure the accuracy of the analysis.
The DNA sequence of each microsatellite in the tumor
was compared with that of the matched normal mucosa.
It was considered as unstable if there was an absence,
shortening or prolongation of the DNA sequence. MSI-L
was defined as 1 unstable microsatellite out of 5, while
MSI-H was defined as more than 1 unstable microsatellite
out of 5. If the tumor microsatellites were identical to
those of the normal tissue, the microsatellite was consid-
ered as stable (MSS).
For the MSI-L CRCs, BAT-40 and MYCL were detected. If
either of these two markers was unstable, this colorectal
sample was considered as MSI-H.
Immunohistochemical staining for MSH2, MSH6 and 
MLH1 on TMAs
The CRC microarray was constructed as previously
described [8,9]. Briefly, formalin-fixed paraffin-embed-
ded tissue blocks of CRC resections were cut from the
donor block and stained with hematoxylin-eosin (HE).
These slides were used to guide the sampling from mor-
phologically representative regions of the tissues. A tissue
array instrument (Beecher Instruments, Silver Spring,
MD) was used to create holes in a recipient paraffin block
and to acquire tissue cores from the donor block by a thin-
walled needle with an inner diameter of 1.0 mm, held in
an X-Y precision guide. The cylindrical samples were
retrieved from the selected regions in the donors and
extruded directly into the recipient blocks with defined
array coordinates. Three cores were obtained from each
sample. After the construction of the array block, multiple
4-mm thick sections were cut with a microtome using an
adhesive-coated tape sectioning system (Instrumedics,
Hackensack, NJ). In our analysis the rates of lost cases
attributable to tissue damage were less than 5% for the
different markers.
TMA slides were stained with MLH1 antibodies (1:50
dilution, No. sc-494, Santa Cruz, Biotrade Ltd, Shanghai,
China) and MSH2 (1:100 dilution, No. sc-581, Santa
Cruz, Biotrade Ltd, Shanghai, China). IHC staining for
samples on the tissue microarray was carried out using
Envision ready-to-use methods (Dako Diagnostics, Zug,
Switzerland). Slides were deparaffinized in xylene and
rehydrated through graded concentrations of ethanol to
distilled water, and endogenous peroxidase activity was
blocked by incubation with 30 mL/L H2O2 in methanol
for 10 min at room temperature. Then sections were sub-
mitted to antigen retrieval in a pressure cooker containing
0.01 mmol/L natrium citricium buffer for 10 min. Slides
were subsequently incubated in 100 mL/L normal goat
serum for 20 min at room temperature. Sections were per-
meabilized in PBS-Triton and incubated overnight with
primary antibody at 4°C. The pathologist and technician
who reviewed the immunostaining of the tissue samples
were blinded to the patient's information. Stained slides
and individual cores were scored as either positive (show-
ing nuclear staining in at least some tumor cells) or nega-
tive.
Detection of methylation of MLH1 promoter by 
quantitative MSP
DNA was chemically modified by sodium bisulfite to con-
vert all unmethylated cytosines to uracils, while leaving
methylcytosines unaltered (EZ DNA methylation gold kit;
Zymo Research, Orange, CA), and eluted in 50 μL of elu-
tion buffer [10,11]. The bisulfite-modified DNA was then
used as a template for the fluorescence-based real-time
PCR assay [12].
The sequences of primers and the fluorogenic probe were
designed by MethPrimer software. Primer sequence for
hMLH1 was: CGTTATATATCGTTCGTAGTATTCGT-
GTTT(Forward), and CTATCGCCGCCTCATCGT
(Reverse), probe sequence was 6FAM-CGCGACGT-
CAAACGCCACTACG-TAMRA. For the MSP, 5 μL of
bisulfite-converted DNA was used in each amplification.
PCR was performed in a reaction volume of 25 μL consist-
ing of 5 pmol of each primer, 250 pmol of probe, 200 μM
each of dATP, dCTP, and dGTP, 400 μM dUTP, 3.5 mM
MgCl2, 1× TaqMan Buffer A, and 2 units of AmpliTaq
Gold polymerase (Applied Biosystem Shanghai Division,
Shanghai, China) at the following condition: 95°C for 10
min, followed by 50 cycles at 95°C for 15 s, and 60°C for
1 min. All PCR was performed in the ABI-7000 Real-Time
PCR Detection system (Applied Biosystem Shanghai Divi-
sion, Shanghai, China). CpGenomeTM Universal methyl-
ated DNA (Chemicon International Inc., city, CA, USA)
was included as positive control in all amplifications and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
quantification of all untreated DNA was used as loading
control.
Extraction of genomic DNA from blood
Blood from peripheral veins (2 mL) was taken from
patients with MSI colorectal cancer, and genomic DNA
was extracted using a kit from Beijing Bio-Lab Materials
Institute. The extracted genomic DNA was stored at -80°C
until further analysis.
Mutation of MSH2, MLH1 and MSH6 genes
Primers for all exons of MSH2, MLH1 and MSH6 were
designed for PCR amplification as previously reported.
PCR amplification was performed using the reagents from
ABI Company, following the protocol provided by theBMC Cancer 2008, 8:44 http://www.biomedcentral.com/1471-2407/8/44
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company. After amplification, the PCR products were
purified by electrophoresis through a 1.5% low melting
point agarose gel, and then were sequenced on an
AB13100-Avant sequencer (Applied Biosystem Shanghai
Division) using fluorescently labeled primers, following
the protocols supplied by the manufacturer. By compar-
ing the obtained sequence with the known sequence, non-
sense, missense, and frameshift mutations were
identified. Nonsense and frameshift mutations were con-
sidered pathogenic. All missense mutations were screened
in 50 patients with MSS colorectal cancer and 50 people
without cancer or a family history of cancer. They were
judged as pathogenic if they could not be found in MSS
patients and normal people, otherwise, they were judged
as polymorphisms.
Statistical methods
The data are presented as mean and standard deviation (x
± SD) or percentage. Student t-test, chi-square test or Log-
rank test were used for statistic analysis as appropriate
(SPSS Inc., Chicago, IL, USA), with p < 0.05 indicating sta-
tistical significance.
Results
One hundred fifty-eight patients received treatment for
colorectal cancer in our Colorectal Center from October
2004 to June 2006. Three patients were excluded for con-
comitant ulcerative colitis and two for unresectable dis-
eases. Five patients refused operation and 2 patients
refused to participate in the study. 146 patients (84 male
and 62 female, age: 60.8 ± 10.5 yr) were recruited into the
study. Clinicopathological features of those patients are
summarized in Table 1.
The results of the MSI analysis, hypermethylation of 
MLH1 and IHC staining of MSH2, MSH6 and MLH1
With the original NCI five marker panel, 34 of 146
patients (23.2%) were MSI, 17 were MSI-H and another
17 were MSI-L. Two out of 17 MSI-L CRCs were unstable
with BAT-40 and were judged as MSI-H. Seven out of 17
MSI-H CRCs were unstable with BAT-40. In all, 19 CRCs
(55.9%) were MSI-H and 15 cancers (44.1%) were MSI-L.
The remaining 112 patients (76.8% were MSS. In the MSI
group, 13 patients (8.9%) were BAT-26 unstable, 18
(12.3%) were BAT-25 unstable, 16 (11.0%) were D2S123
unstable, 11 (7.5%) were D5S346 unstable, 14 (9.6%)
were D17S250 unstable.
Negative staining for MSH2 was found in 8 CRCs, nega-
tive staining for MSH6 was found in 6 CRCs. One MSI-H
CRC was negative for both MSH6 and MSH2. Seventeen
CRCs stained negatively for MLH1. Negative staining was
not found in three MSI CRCs, and one CRC was found
with negative MLH1 staining, but it was MSS.
MLH1 promoter methylation was determined in 34 MSI
CRCs. Hypermethylation of the MLH1 promoter occurred
in 14 (73.7%) out of 19 MSI-H CRCs and 5 (33.3%) out
15 MSI-L CRCs. The results of MSI and IHC staining are
summarized in Table 2.
Comparison of clinical features between MSI and MSS 
colorectal cancers
Table 3 summarizes the clinical features of MSS and MSI
patients. Patients in the MSS group are younger than those
in MSI group (70.9 ± 17.8 versus 61.0 ± 9.4, p = 0.045).
Twenty out of 34 (59%) MSI patients were stage III or
stage IV, significantly higher than those (35.7%) in the
MSS group (p = 0.008). There were no differences in other
Table 2: The result of MSI, hypermethylation of MLH1 and IHC 
staining
IHC(-) MSH2 MSH6 MLH1 None Hypermethylation 
of MLH1
MSI-H 8* 4* 7 1 14
M S I - L 13925
M S S 0011 1 1 n . a . #
*One MSI-H CRCs was negative both for MSH6 and MSH2
# MLH1 promoter methylation was determined only in MSI CRCs.
Table 1: Clinicopathological features of cases (N = 146)
Cases Amount





ascending colon 24 (16.3%)
transverse colon 15 (10.3%)
descending colon 13 (8.9%)




metachronous tumour 7 (4.5%)
Pathology:
adenocarcinoma 93 (63.7%)
mucinous carcinoma 23 (15.8%)
mixed type 30 (20.5%)
Dukes stage*:






*Astler-Coller Dukes stageBMC Cancer 2008, 8:44 http://www.biomedcentral.com/1471-2407/8/44
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demographic and clinical pathological features, including
sex, tumor location and type between the two groups. The
most common location of the tumor was the rectum in
both groups, accounting for more than 50% of the cases.
Adenocarcinoma was the most common pathological
type in both groups. Ten patients in the MSI group
(29.4%) had mucinous carcinoma.
MSI state, germline mutations, and consequential changes 
in amino-acid sequence
The MSI state, mutation sites, and consequential changes
in amino-acid sequences of MMR genes are summarized
in Table 4. In 34 MSI CRCs and one MSS CRC with MLH1
negative staining, 8 had MMR gene germline mutations,
accounting for 22.9% of MSI colorectal cancers and 5.5%
of all colorectal cancers. Three patients had MSH6 germ-
line mutations and 5 had MSH2 germline mutations; the
clinical features of these patients are summarized in Table
5. None of the patients had MLH1 gene mutations. Seven
patients in the MSI group had A/T heterozygosis in MSH6
codon 380 of exon 5, but it did not cause changes in the
amino acid sequence. The germline mutations of the MSI-
L and MSI-H CRCs are summarized in Table 6. Six CRCs
Table 4: Details of the 8 patients in MSS group identified to have MMR gene germline mutation
Patient No. MSI state Mutant gene Exon Mutation site Change in amino 
acid sequence
2 L MSH2 12 c.1886 A > G p.629 Gln > Arg
28 H MSH2 7 c.1225 C > A p.409 Gln > Lys
93 L MSH6 5 c.3200 C > A p.1067 Pro > His
98 H MSH2 12 c.1886 A > G p.629 Gln > Arg
115 H MSH6 2 c.440 T > A p.149 Leu > His
119 H MSH2 7 c.1145 G > A p.382 Arg > His
132 H MSH6 5 c.3185 C > T p.1062 Pro > Leu
151 H MSH2 7 c.1168 C > T p.390 Phe > Leu
Table 3: Comparisons of clinical features between MSS and MSI group
MSS (n = 112) MSI (n = 34) P-value
MSI-L (n = 15) MSI-H (n = 19)
Mean age (range) 60.0 (26–84) 71.9 ± 17.8 60.4 ± 9.4 0.010
Gender
Male 67 8 12 0.207
Female 45 7 7
Location of tumor 0.658
Ascending colon 19 1 4
Transverse colon 9 1 4
Descending colon 10 2 0
Sigmoid flexure 11 1 4
Rectum 61 10 7
Pathological type 0.545
Adenocarcinoma 71 11 13
Mucinous cancer 39 4 6
Mixture type 2 0 0
Dukes' Staging# 0.008
Stage I 15 2 0
Stage II 57 5 7
Stage III 34 6 8
Stage IV 6 2 4
Degree of differentiation 0.169
Well 35 6 5
Moderate 58 3 6
Poor 11 6 8
*Statistical analysis was made between MSI and MSS group onlyBMC Cancer 2008, 8:44 http://www.biomedcentral.com/1471-2407/8/44
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with mutations were MSI-H and two patients with muta-
tions were MSI-L.
Clinical features of patients in the MSI group with MMR 
gene mutations
The clinical features of MSI patients with MMR gene muta-
tions are shown in Table 5. Mean age was 58.8 years
(range: 34–78). Six were female and 2 were male. Only
one patient had right side colonic lesion and 2 had muci-
nous carcinoma. There were no patients in Dukes' A or
with synchronous/metachronous disease. Only one
patient fulfilled the Amsterdam Criteria (II).
Discussion
Identification of mismatch repair gene germline muta-
tions in sporadic colorectal cancer is the most important
method to screen HNPCC. In 2004, the NCI recom-
mended the revised Bethesda criteria as a HNPCC screen-
ing guideline and established the HNPCC diagnostic
procedures. These guidelines stated that MSI should firstly
be identified in colorectal tumor tissue, and then genetic
tests would be performed to confirm MMR gene germline
mutations in a blood sample [6].
At present, a number of publications have studied the
value of the revised Bethesda criteria and the relevant
diagnostic procedures [13,14]. However, there has not
been any systematic report on germline mutations of
MMR genes in the Chinese population. Moreover, we
found that research from some countries have results that,
if applied to the NCI recommendations, may have
resulted in a missed HNPCC family or low pick-up rate of
HNPCC. In a study by Pinol et al. from Spain [13], 287
out of 1222 patients (23.5%) complied with the revised
Bethesda standard. Ninety-one patients (7.4%) were MSI
carriers, but only 11 patients (0.9%) had germline muta-
tions of MSH2 or MLH1. This means that among this
group, only 0.9% of patients could be diagnosed as
HNPCC. In a study by Yearsley et al. [14], out of 482 US
patients with colorectal cancers, 87 patients (18%) were
MSI carriers and only 12 cases (2.5%) had MMR gene
germline mutations. These results may be explained by
different case selections and sensitivity of the tests used.
On the other hand, in their study of HNPCC related
tumors in young patients (<50 years old), Niessen et al.
[15] found that the rate of MSH2, MSH6 and MLH1 germ-
line mutations in MSI carriers was 82%. In our 146
patients with colorectal cancers, 34 patients (23.3%) had
MSI colorectal cancer. This is comparable to the studies by
Pinol et al. [13] and Yearsley et al. [16]. Wong et al. [17]
showed that in the case of sporadic endometrial carci-
noma, MSI endometrial carcinoma accounted for 26% of
patients. Our results showed that there were 15 (10.3%)
CRCs with MSI-L and 19 (13.0%) CRCs with MSL-H,
respectively. Lamberti et al. [18] reported that MSI-L and
MSI-H accounted for 6% and 17%, respectively, of Ger-
man patients. These results are similar to ours. Unexpect-
edly, in the present study, the age of patients with MSS
colorectal cancers (60 yrs) was similar to the age of
patients with MSI-H (61 yrs). In contrast, the average age
of patients with MSI-L colorectal cancer was 71, which
was quite different from the reports of other research
groups [13,15,18]. In a study of 1263 patients with color-
ectal cancers, Benatti et al. [19] found that those who were
MSI carriers tended to have mucinous and right colonic
tumours. Noda et al. [20] also found that MSI carriers
have more right colonic tumors. However, in our study,
Table 6: The mutation between the MSI-L and MSI-H
NM u t a t i o n
total MSH2 MSH6
M S I - L1 7 211
M S L - H 1 7 642
t o t a l 3 4 853
P = 0.112
Table 5: Clinical features of patients in MSI group with MMR gene mutations








2 49 F Sigmoid Adenocarcinoma C1 H No No
28 54 F Rectum Adenocarcinoma B1 H No No
93 68 M Rectum Adenocarcinoma B2 L No No
98 78 F Sigmoid Mucinous carcinoma B1 H No No
115 57 F Rectum Adenocarcinoma C2 L No No
119 61 F Rectum Adenocarcinoma B1 H No No
124 34 F Hepatic Flexure Mucinous carcinoma C2 H Yes* No
151 68 F Rectum Adenocarcinoma C1 H No No
*Amsterdam criteria IIBMC Cancer 2008, 8:44 http://www.biomedcentral.com/1471-2407/8/44
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tumors in the MSI group were most commonly located at
the rectum, and mucinous carcinoma was not the most
common pathological type, as it only accounted for 29%.
Interestingly, patients in our MSI-L group were older than
the MSS group. The reason for these findings is uncertain.
Bettstetter et al. [20] reported that the average age of MSI
CRCs with MLH1 negative staining was 80 yrs, which was
similar to our results. Most of these MSI CRCs were caused
by MLH1 promoter hypermethylation. In our group, out
of 34 MSI CRCs, 19 CRCs (55.9%) were hypermethylated
at the MLH1 promoter, which accounted for 73.7% of
MSI-H CRCs and 33.3% of MSI CRCs. Anacleto et al. [21]
reported that 8 out of 15 MSI CRCs had MLH1 promoter
hypermethylation, which was similar to our results. Kim
et al. [10] found that in MSI-H gastric cancers, the MLH1
hypermethylation occurred in 89% of patients. Bettstetter
et al. [20] showed that all sporadic MSI-H CRCs were
hypermethylated at the MLH1 promoter. These results
were similar to ours. Fourteen out of 16 MLH1 negatively
staining CRCs were hypermethylated at the
MLH1promoter. Mutation analysis revealed that 8
patients (23.5%) had MMR gene germline mutations out
of 34 MSI patients. Five patients had MSH2 mutations
and 3 had MSH6 mutations, while no MLH1 mutation
was found. There were 2 and 6 patients who had muta-
tions in MSH2 and MSH6 in the MSI-L and MSI-H groups,
respectively. Yearsley et al. [15], in their study of 87
patients with MSI colorectal cancers, found 12 patients
(13.8%) with MLH1 and MSH2 germline mutations.
Niessen et al. [16], however, found that the rate of MSH2,
MSH6 and MLH1 germline mutations was 82% in the
young age group (<50 years old). This was quite different
from our group. This difference might be due to different
case selections of the two groups. Our study was more rep-
resentative of the patient population because it was a suc-
cessive cohort study. Most importantly, the above
differences may also be explained by underlying differ-
ences in genetic background between Chinese and West-
ern populations.
Regarding the location of gene mutations, we found that
3 patients bore mutations in exon 7 of MSH2, 2 had muta-
tions in exon 12 of MSH2, 1 had a mutation in exon 2 of
MSH6, and 2 had mutations in exon 5 of MSH6. No
MLH1 mutations were found in our cohort. All 8 muta-
tions were considered pathogenic mutations. The muta-
tion of C1886 A > G, C1668 C > T was reported as a
pathogenic mutation previously [22-25]. However, the
other six mutations have not been reported in other pub-
lications and are likely to be novel mutations. We also
attempted to screen for the presence of all these mutations
in 50 randomly selected patients in the MSS group and in
50 normal people. The result of this screen was negative,
and all these CRCs with mutations stained negatively for
MSH2 or/and MSH6, indicating that these 6 mutations
may be pathogenic mutations but not polymorphisms. In
terms of the clinical features of the 8 cases with mutations,
only 1 conformed to the Amsterdam criteria II; all the oth-
ers did not have any family history of malignancy. More-
over, the median age was 59 with 4 patients that were
older than 60 years old.
One limitation of this study is that it is a single-center
study with a relatively small sample size. Therefore, the
results of this study need to be confirmed by a well
designed multi-center study, which is one of our ongoing
studies in China.
Conclusion
Our results imply that HNPCC in the Chinese population
may have distinct clinicopathological characteristics and
underlying MMR germline mutations, as compared to
patients from Western countries. Application of NCI rec-
ommendations on the Chinese population may not ena-
ble the screening of all HNPCC families. Further studies
are necessary to echo or refute our results so as to make the
NCI recommendation more universally applicable.
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